Recent news on

Inflammatory bowel disease: next-generation TNF's threat to Remicade  -  Dec 1, 2006
Pharmaceutical Business ReviewUCB is also set to be a substantial future player following its acquisition of Celltech, and with that Cimzia and Dipentum.

Column: Learning to stomach a delicate condition  Oct 9, 2006
We shouted nouns the average college student should expect to hear at a rock show. Nouns like "barium" and "Dipentum" and "colonoscopy.". ... -The Daily Advertiser, Salix Pharmaceuticals Reports American College of Gastroenterology ...  Oct 24, 2006
Therapy consisted of Asacol(R) 400/800 mg/d, Pentasa(R) 250-500 mg/d, COLAZAL 750-1500 mg/d or Dipentum(R) 500-1,000 mg/d. Treatment response was defined as ... -Genetic Engineering News (press release), Inflammatory bowel disease: next-generation TNF's threat to Remicade  -  Dec 1, 2006
Pharmaceutical Business ReviewUCB is also set to be a substantial future player following its acquisition of Celltech, and with that Cimzia and Dipentum.

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional